Medical Oncology Division, Policlinico Hospital, Perugia, Italy.
N Engl J Med. 1995 Jan 5;332(1):1-5. doi: 10.1056/NEJM199501053320101.
Serotonin-receptor antagonists seem to be as effective as corticosteroids in preventing emesis induced by moderately emetogenic antineoplastic agents. We compared the antiemetic effect of a combination of granisetron and dexamethasone with that of granisetron or dexamethasone administered alone.
From December 1992 to January 1994, 482 consecutive patients who were to receive moderately emetogenic chemotherapy for the first time (600 to 1000 mg of cyclophosphamide per square meter of body-surface area, > or = 50 mg of doxorubicin per square meter, > or = 75 mg of epirubicin per square meter, or > or = 300 mg of carboplatin per square meter, alone or in some combination) were enrolled in a double-blind, randomized, multi-center study evaluating the efficacy and toxicity of three antiemetic regimens. The following antiemetic regimens were used: 8 mg of dexamethasone given intravenously before chemotherapy plus 4 mg given orally immediately before chemotherapy and then every six hours for a total of four doses, 3 mg of granisetron given intravenously before chemotherapy, or a combination of granisetron and dexamethasone given in the doses used for the single-drug regimens.
We evaluated 408 patients (136 receiving dexamethasone, 137 receiving granisetron, and 135 receiving both drugs). In the first 24 hours after chemotherapy, complete protection from vomiting and complete protection from nausea were achieved in 70.6 and 55.1 percent, respectively, of the patients receiving dexamethasone, in 72.3 and 48.2 percent of those receiving granisetron, and in 92.6 and 71.9 percent of those receiving granisetron combined with dexamethasone (P < 0.001 for all comparisons). Patients who received granisetron alone had less protection from delayed vomiting and nausea than those who received dexamethasone alone or the two drugs combined. All the regimens were equally well tolerated.
Granisetron combined with dexamethasone was the most effective regimen for the prevention of emesis induced by moderately emetogenic chemotherapy.
5-羟色胺受体拮抗剂在预防由中度致吐性抗肿瘤药物引起的呕吐方面似乎与皮质类固醇一样有效。我们比较了格拉司琼与地塞米松联合用药和单独使用格拉司琼或地塞米松的止吐效果。
从1992年12月至1994年1月,482例首次接受中度致吐性化疗的连续患者(每平方米体表面积接受600至1000mg环磷酰胺、每平方米≥50mg阿霉素、每平方米≥75mg表柔比星或每平方米≥300mg卡铂,单独或联合使用)被纳入一项双盲、随机、多中心研究,评估三种止吐方案的疗效和毒性。使用了以下止吐方案:化疗前静脉注射8mg地塞米松,化疗前即刻口服4mg,然后每6小时一次,共4剂;化疗前静脉注射3mg格拉司琼;或按单药方案的剂量联合使用格拉司琼和地塞米松。
我们评估了408例患者(136例接受地塞米松治疗,137例接受格拉司琼治疗,135例接受两种药物治疗)。化疗后的前24小时内,接受地塞米松治疗的患者中分别有70.6%和55.1%完全预防了呕吐和恶心,接受格拉司琼治疗的患者中分别有72.3%和48.2%,接受格拉司琼联合地塞米松治疗的患者中分别有92.6%和71.9%(所有比较P<0.001)。单独接受格拉司琼治疗的患者对延迟性呕吐和恶心的预防效果不如单独接受地塞米松治疗或两种药物联合治疗的患者。所有方案的耐受性均良好。
格拉司琼联合地塞米松是预防中度致吐性化疗引起呕吐的最有效方案。